Currently, many drugs including temsirolimus, everolimus, rapamycin, INK-128, OSI027, AZD8055, GSK690693, MK-2206, CAL-101, BYL719, PX866, GDC0941, BKM120, and ZSTK474 that target PI3K/Akt have been investigated in phases I to III clinical trials [111], among which, temsirolimus and everolimus have been found with remarkable efficacies in treating thyroid cancers [61-63]. This evidence concerns the gene AKT1 and thyroid cancer.